Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; Guides Modestly Below the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Johnson & Johnson (JNJ) PT Lowered to $141 at UBS Following 4Q Report
January 25, 2017 8:12 AM ESTUBS lowered its price target on Johnson & Johnson (NYSE: JNJ) to $141.00 (from $142.00) while maintaining a Buy rating following the company's 4Q earnings report.
Analyst Matt Miksic commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up... More
